Search

Displaying results 5251 - 5260 of 10000 in total
  1. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da. … The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  2. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da. … Paltimatrectinib is under investigation in clinical trial NCT04901806 (Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors).

  3. Drug

    Ofirnoflast

    go.drugbank.com/drugs/DB21679
    Investigational

    Ofirnoflast is under investigation in clinical trial NCT07052006 (HT-6184 in Subjects With MDS). Ofirnoflast has a monoisotopic molecular weight of 501.15 Da. … The usage of the INN stem '-noflast' in the name indicates that Ofirnoflast is a inflammasome protein NLRP3 inhibitor.

  4. Drug

    Aldesleukin

    go.drugbank.com/drugs/DB00041
    ApprovedInvestigational

    This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon … Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene.

    Products: PROLEUKIN 18X106 IU/ML STERİL IV LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADET
  5. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded … This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes.

  6. Drug

    Dibekacin

    go.drugbank.com/drugs/DB13270
    Approved

    Dibekacin is an aminoglycoside antibiotic marketed in Japan [L5623].

  7. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment … The drug is composed of an IL-6–binding trimer and a IgG-binding domain.

  8. Drug

    Bucainide

    go.drugbank.com/drugs/DB20650
    Experimental

    The usage of the INN stem '-cain-' in the name indicates that Bucainide is a class I antiarrhythmic, procainamide and lidocaine derivative. Bucainide has a monoisotopic molecular weight of 329.28 Da.

  9. Drug

    Carperone

    go.drugbank.com/drugs/DB21088
    Experimental

    Carperone has a monoisotopic molecular weight of 350.2 Da. … The usage of the INN stem '-perone' in the name indicates that Carperone is a tranquillizer, neuroleptic, 4'-fluoro-4-piperidinobutyrophenone derivative.

  10. Drug

    Pentamustine

    go.drugbank.com/drugs/DB21291
    Experimental

    Pentamustine has a monoisotopic molecular weight of 221.09 Da. … The usage of the INN stem '-mustine' in the name indicates that Pentamustine is a antineoplastic, alkylating agent, (β-chloroethyl) amine derivative.